Pasar al contenido principal

TRANSICION MESOTELIAL A MESENQUIMAL: UN PROCESO PATOLOGICO IMPORTANTE EN ENFERMEDADES QUE AFECTAN EL PERITONEO

PID2019-110132RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Increased miR-7641 levels in peritoneal hyalinizing vasculopathy in long-term peritoneal dialysis patients

  • Díaz, Raquel
  • Sandoval, Pilar
  • Rodrigues-Diez, Raul R.
  • Peso, Gloria del
  • Jiménez-Heffernan, José A.
  • Ramos-Ruiz, Ricardo
  • Llorens, Carlos
  • Laham, Gustavo
  • Alvarez-Quiroga, Mabel
  • López Cabrera, Manuel
  • Ruiz-Ortega, Marta
  • Bajo, María A.
  • Selgas, Rafael
Peritoneal hyalinizing vasculopathy (PHV) represents the cornerstone of long-term peritoneal dialysis (PD), and especially characterizes patients associated with encapsulating peritoneal sclerosis. However, the mechanisms of PHV development remain unknown. A cross sectional study was performed in 100 non-selected peritoneal biopsies of PD patients. Clinical data were collected and lesions were evaluated by immunohistochemistry. In selected biopsies a microRNA (miRNA)-sequencing analysis was performed. Only fifteen patients (15%) showed PHV at different degrees. PHV prevalence was significantly lower among patients using PD fluids containing low glucose degradation products (GDP) (5.9% vs. 24.5%), angiotensin converting enzyme inhibitors (ACEIs) (7.5% vs. 23.4%), statins (6.5% vs. 22.6%) or presenting residual renal function, suggesting the existence of several PHV protective factors. Peritoneal biopsies from PHV samples showed loss of endothelial markers and induction of mesenchymal proteins, associated with collagen IV accumulation and wide reduplication of the basement membrane. Moreover, co-expression of endothelial and mesenchymal markers, as well as TGF-β1/Smad3 signaling activation were found in PHV biopsies. These findings suggest that an endothelial-to-mesenchymal transition (EndMT) process was taking place. Additionally, significantly higher levels of miR-7641 were observed in severe PHV compared to non-PHV peritoneal biopsies. Peritoneal damage by GDPs induce miRNA deregulation and an EndMT process in submesothelial vessels, which could contribute to collagen IV accumulation and PHV., This research was funded by grants from the Instituto de Salud Carlos III (ISCIII) and Fondos FEDER European Union (PI15/00120 to R.S, PI18/00882 to M.A.B, PI17/00119 to M.R.-O. and Red de Investigación Renal (REDINREN): RD16/0009, to R.S and M.R-O); “Convocatoria Dinamización Europa Investigación 2019” MINECO (EIN2019-103294 to M.R.-O.); IMPROVE-PD project (“Identification and Management of Patients at Risk–Outcome and Vascular Events in Peritoneal Dialysis”) funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 812699 to M.R.-O. and M.L-C. Spanish Ministry of Science and Innovation/Fondo Europeo de Desarrollo Regional (MICINN/FEDER) (PID2019-110132RB-I00) to M.L.-C., Peer reviewed, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel aspects of the immune response involved in the peritoneal damage in chronic kidney disease patients under dialysis

  • Trionfetti, Flavia
  • Marchant, Vanessa
  • González-Mateo, Guadalupe
  • Kawka, Edyta
  • Márquez-Expósito, Laura
  • Ortiz, Alberto
  • López Cabrera, Manuel
  • Ruíz-Ortega, Marta
  • Strippoli, Raffaele
Chronic kidney disease (CKD) incidence is growing worldwide, with a significant percentage of CKD patients reaching end-stage renal disease (ESRD) and requiring kidney replacement therapies (KRT). Peritoneal dialysis (PD) is a convenient KRT presenting benefices as home therapy. In PD patients, the peritoneum is chronically exposed to PD fluids containing supraphysiologic concentrations of glucose or other osmotic agents, leading to the activation of cellular and molecular processes of damage, including inflammation and fibrosis. Importantly, peritonitis episodes enhance peritoneum inflammation status and accelerate peritoneal injury. Here, we review the role of immune cells in the damage of the peritoneal membrane (PM) by repeated exposure to PD fluids during KRT as well as by bacterial or viral infections. We also discuss the anti-inflammatory properties of current clinical treatments of CKD patients in KRT and their potential effect on preserving PM integrity. Finally, given the current importance of coronavirus disease 2019 (COVID-19) disease, we also analyze here the implications of this disease in CKD and KRT., This research was funded by grants from the Instituto de Salud Carlos III (ISCIII) and Fondos FEDER European Union (PI20/00140, PI19/00815, and DTS20/00083). Red de Investigación Renal REDINREN: RD16/0009/0003 to M.R-O and RICORS2040; RD21/0005/0002 funded by European Union—NextGenerationEU, Sociedad Española de Nefrología. Innovation programme under the Marie Skłodowska-Curie grant of the European Union’s Horizon 2020 (IMPROVE-PD ID: 812699) to M.R-O. E.K. was supported by the grant from the Narodowe Centrum Nauki (NCN, Polish National Science Centre; 2018/29/N/NZ3/02504). R.S. was supported by Ministry for Health of Italy (Ricerca Corrente). This work was also supported by a grant (PID 2019-110132RB-I00/AEI/10.13039/501100011033) from the Spanish Ministry of Science and Innovation/Fondo Europeo de Desarrollo Regional (MICINN/FEDER) to M.L.-C., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting carcinoma-associated mesothelial cells with antibody-drug conjugates in ovarian carcinomatosis

  • Pascual-Antón, Lucía
  • Sandoval, Pilar
  • González-Mateo, Guadalupe T.
  • Kopytina, Valeria
  • Tomero-Sanz, Henar
  • Arriero-País, Eva María
  • Jiménez-Heffernan, José Antonio
  • Fabre, Myriam
  • Egaña, Isabel
  • Ferrer, Cristina
  • Simón, Laureano
  • González-Cortijo, Lucía
  • Sainz de la Cuesta, Ricardo
  • López-Cabrera, Manuel
Ovarian carcinomatosis is characterized by the accumulation of carcinoma-associated mesothelial cells (CAMs) in the peritoneal stroma and mainly originates through a mesothelial-to-mesenchymal transition (MMT) process. MMT has been proposed as a therapeutic target for peritoneal metastasis. Most ovarian cancer (OC) patients present at diagnosis with peritoneal seeding, which makes tumor progression control difficult by MMT modulation. An alternative approach is to use antibody-drug conjugates (ADCs) targeted directly to attack CAMs. This strategy could represent the cornerstone of precision-based medicine for peritoneal carcinomatosis. Here, we performed complete transcriptome analyses of ascitic fluid-isolated CAMs in advanced OC patients with primary-, high-, and low-grade, serous subtypes and following neoadjuvant chemotherapy. Our findings suggest that both cancer biological aggressiveness and chemotherapy-induced tumor mass reduction reflect the MMT-associated changes that take place in the tumor surrounding microenvironment. Accordingly, MMT-related genes, including fibroblast activation protein (FAP), mannose receptor C type 2 (MRC2), interleukin-11 receptor alpha (IL11RA), myristoylated alanine-rich C-kinase substrate (MARCKS), and sulfatase-1 (SULF1), were identified as specific actionable targets in CAMs of OC patients, which is a crucial step in the de novo design of ADCs. These cell surface target receptors were also validated in peritoneal CAMs of colorectal cancer peritoneal implants, indicating that ADC-based treatment could extend to other abdominal tumors that show peritoneal colonization. As proof of concept, a FAP-targeted ADC reduced tumor growth in an OC xenograft mouse model with peritoneal metastasis-associated fibroblasts. In summary, we propose MMT as a potential source of ADC-based therapeutic targets for peritoneal carcinomatosis., This work was supported by the following grants to MLC: Spanish Ministry of Science and Innovation/Fondo Europeo de Desarrollo Regional (MICINN/FEDER) Grant PID2019-110132RB-I00/AEI/10.13039/501100011033 and Marie Sklodowska-Curie Innovative Training Networks-European Training Networks Grant 812699., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

HDAC1/2 control mesothelium/ovarian cancer adhesive interactions impacting on Talin-1-α5β1-integrin-mediated actin cytoskeleton and extracellular matrix protein remodeling

  • Terri, Michela
  • Sandoval, Pilar
  • Bontempi, Giulio
  • Montaldo, Claudia
  • Tomero-Sanz, Henar
  • Turris, Valeria de
  • Trionfetti, Flavia
  • Pascual-Antón, Lucía
  • Clares, Irene
  • Battistelli, Cecilia
  • Valente, Sergio
  • Zwergel, Clemens
  • Mai, Antonello
  • Rosanò, Laura
  • Pozo, Miguel Angel
  • Sánchez-Álvarez, Miguel
  • Cabañas, Carlos
  • Tripodi, Marco
  • López-Cabrera, Manuel
  • Strippoli, Raffaele
[Background]: Peritoneal metastasis, which accounts for 85% of all epithelial ovarian carcinoma (EOC) metastases, is a multistep process that requires the establishment of adhesive interactions between cancer cells and the peritoneal membrane. Interrelations between EOC and the mesothelial stroma are critical to facilitate the metastatic process. No data is available so far on the impact of histone acetylation/deacetylation, a potentially relevant mechanism governing EOC metastasis, on mesothelial cells (MCs)-mediated adhesion., [Methods]: Static adhesion and peritoneal clearance experiments were performed pretreating mesenchymal-like MCs and platinum—sensitive/resistant EOC cell lines with MS-275—a Histone deacetylase (HDAC)1–3 pharmacological inhibitor currently used in combination trials. Results were acquired by confocal microscopy and were analyzed with an automated Opera software. The role of HDAC1/2 was validated by genetic silencing. The role of α4-, α5-α1 Integrins and Fibronectin-1 was validated using specific monoclonal antibodies. Quantitative proteomic analysis was performed on primary MCs pretreated with MS-275. Decellularized matrices were generated from either MS-275-exposed or untreated cells to study Fibronectin-1 extracellular secretion. The effect of MS-275 on β1 integrin activity was assessed using specific monoclonal antibodies. The role of Talin-1 in MCs/EOC adhesion was analyzed by genetic silencing. Talin-1 ectopic expression was validated as a rescue tool from MS-275-induced phenotype. The in vivo effect of MS-275-induced MC remodeling was validated in a mouse model of peritoneal EOC dissemination., [Results]: Treatment of MCs with non-cytotoxic concentrations of MS-275 caused a consistent reduction of EOC adhesion. Proteomic analysis revealed several pathways altered upon MC treatment with MS-275, including ECM deposition/remodeling, adhesion receptors and actin cytoskeleton regulators. HDAC1/2 inhibition hampered actin cytoskeleton polymerization by downregulating actin regulators including Talin-1, impairing β1 integrin activation, and leading to abnormal extracellular secretion and distribution of Fibronectin-1. Talin-1 ectopic expression rescued EOC adhesion to MS-275-treated MCs. In an experimental mouse model of metastatic EOC, MS-275 limited tumor invasion, Fibronectin-1 secretion and the sub-mesothelial accumulation of MC-derived carcinoma-associated fibroblasts., [Conclusion]: Our study unveils a direct impact of HDAC-1/2 in the regulation of MC/EOC adhesion and highlights the regulation of MC plasticity by epigenetic inhibition as a potential target for therapeutic intervention in EOC peritoneal metastasis., This research was funded by: AIRC (Associazione Italiana per la Ricerca sul Cancro) (IG26172) and Ateneo Sapienza Project 2020 (RG120172B8E53D03) to S.V; by FISR2019_00374 MeDyCa to AM; by FSE REACT-EU within the program PON “Research and Innovation” 2014–2020, Action IV.6 “Contratti di ricerca su tematiche Green” to CZ; by SEED PNR 2021 to C.B.; by AIRC IG26290, by Sapienza University of Rome (RG11916B6A9C42C7) to M. Tr and by Ministry for Health of Italy (Ricerca Corrente), by AIRC (IG21372 to LR), by PRIN 2022 PNRR (P2022XZKBM) financed by the European Union - NextGenerationEU», to RS. This work was also supported by grants (PID2019-110132RB-I00/AEI/https://doi.org/10.13039/501100011033 and PID2022-142796OB-I00/AEI/https://doi.org/10.13039/501100011033)) from the Spanish Ministry of Science and Innovation/Fondo Europeo de Desarrollo Regional (MICIN/FEDER) to ML-C and by a grant PID2021-123199OB-I00 from the Spanish Ministry of Science and Innovation/Fondo Europeo de Desarrollo Regional (MICIN/FEDER) to CC. MAdP is recipient/co-recipient of funding from the Spanish Ministry of Science and Innovation (MCIN) (refs. SAF2017–83130-R cofunded by “ERDF A way of making Europe”, PID2020-118658RB-I00, PDC2021–121572-100 cofunded by “European Union NextGeneration EU/PRTR”), Asociación Española Contra el Cáncer foundation (AECC; PROYE20089DELP); La Marató TV3 foundation (201936–30-31), Obra social La Caixa (AtheroConvergence, HR20–00075) and Comunidad Autónoma de Madrid/FEDER (Tec4Bio consortium, ref. S2018/NMT¬4443). MS-A is recipient of a Ramón y Cajal research contract from MCIN (RYC2020–029690-I) and research grant PID2021-128106NA-I00, both from Spanish MCIN. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation), and is a Severo Ochoa Center of Excellence (grant CEX2020–001041-S funded by MICIN/AEI/https://doi.org/10.13039/501100011033)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2020–001041-S)., Peer reviewed